Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on April 3, 2008

Arteriosclerosis, Thrombosis, and Vascular Biology. 2008
Published online before print April 3, 2008, doi: 10.1161/ATVBAHA.108.164210
A more recent version of this article appeared on June 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
28/6/1151    most recent
ATVBAHA.108.164210v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Batenburg, W. W.
Right arrow Articles by Danser, A. H. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Batenburg, W. W.
Right arrow Articles by Danser, A. H. J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Blood Pressure Medicines

Submitted on October 16, 2007
Accepted on March 21, 2008

Aliskiren-Binding Increases the Half Life of Renin and Prorenin in Rat Aortic Vascular Smooth Muscle Cells

Wendy W. Batenburg ; René J.A. de Bruin ; Jeanette M.G. van Gool ; Dominik N. Müller ; Michael Bader ; Geneviève Nguyen ; and A. H. Jan Danser *

From the Erasmus MC (W.W.B., R.J.A.d.B., J.M.G.v.G., A.H.J.D.), Rotterdam, The Netherlands; Max Delbrück Center for Molecular Medicine (D.N.M., M.B.), Berlin, Germany; and the Institut National de Santé et de la Recherche Médicale (Inserm) Unit 833 and Chaire de Médecine Expérimentale (G.N.), Collège de France, Paris, France.

* To whom correspondence should be addressed. E-mail: a.danser{at}erasmusmc.nl.

Objective—Renin inhibition with aliskiren has been reported to cause a greater rise in renin than other types of renin-angiotensin system blockade, thereby potentially leading to angiotensin generation or stimulation of the human (pro)renin receptor (h(P)RR). Here we studied whether this rise in renin is attributable to an aliskiren-induced change in the prorenin conformation, allowing its detection in renin assays, or a change in renin/prorenin clearance. We also investigated whether aliskiren affects (pro)renin binding to its receptors, using rat aortic VSMCs overexpressing the h(P)RR.

Methods and Results—A 48-hour incubation with aliskiren at 4°C converted the prorenin conformation from "closed" to "open," thus allowing its recognition in active site-directed renin assays. VSMCs accumulated (pro)renin through binding to mannose 6-phosphate receptors (M6PRs) and h(P)RRs. Aliskiren did not affect binding at 4°C. At 37°C, aliskiren increased (pro)renin accumulation up to 40-fold, and M6PR blockade prevented this. Aliskiren increased the intracellular half life of prorenin 2 to 3 times.

Conclusion—Aliskiren allows the detection of prorenin as renin, and decreases renin/prorenin clearance. Both phenomena may contribute to the "renin" surge during aliskiren treatment, but because they depend on aliskiren binding, they will not result in angiotensin generation. Aliskiren does not affect (pro)renin binding to its receptors.


Key words: prorenin • renin • aliskiren • half-life • receptor




This article has been cited by other articles:


Home page
Diabetes CareHome page
F. Persson, P. Rossing, H. Reinhard, T. Juhl, C. D.A. Stehouwer, C. Schalkwijk, A.H. J. Danser, F. Boomsma, E. Frandsen, and H.-H. Parving
Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria
Diabetes Care, October 1, 2009; 32(10): 1873 - 1879.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. Cousin, D. Bracquart, A. Contrepas, P. Corvol, L. Muller, and G. Nguyen
Soluble Form of the (Pro)Renin Receptor Generated by Intracellular Cleavage by Furin Is Secreted in Plasma
Hypertension, June 1, 2009; 53(6): 1077 - 1082.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
H.-H. Parving, B. M. Brenner, John. J. V. McMurray, D. de Zeeuw, S. M. Haffner, S. D. Solomon, N. Chaturvedi, M. Ghadanfar, N. Weissbach, Z. Xiang, et al.
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design
Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1663 - 1671.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Krop, I. M. Garrelds, R. J.A. de Bruin, J. M.G. van Gool, N. D.L. Fisher, N. K. Hollenberg, and A.H. Jan Danser
Aliskiren Accumulates in Renin Secretory Granules and Binds Plasma Prorenin
Hypertension, December 1, 2008; 52(6): 1076 - 1083.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
R. Dietz, R. Dechend, C.-M. Yu, M. Bheda, J. Ford, M. F. Prescott, and D. L. Keefe
Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2008; 9(3): 163 - 175.
[Abstract] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
W. W Batenburg and A. J. Danser
Prorenin and the (pro)renin receptor: binding kinetics, signalling and interaction with aliskiren
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2008; 9(3): 181 - 184.
[PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
A. J. Danser and G. Nguyen
Spotlight on Renin: The Renin Academy Summit: advancing the understanding of renin science
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2008; 9(2): 119 - 123.
[PDF]